New Alzheimer’s treatments are bringing hope to families facing a diagnosis. FDA-approved medications, including donanemab (Kisunla) and lecanemab (Leqembi), can slow cognitive decline in some individuals with early Alzheimer’s disease. Advances in blood testing are also helping physicians identify disease-related changes earlier.
While there is no cure for Alzheimer’s, these developments offer families more options.
At Kensington Place Redwood City, we believe understanding those options can help you make informed decisions about your loved one’s care.
Key Takeaways: What’s New in Alzheimer’s Treatment?
- New medications can slow early Alzheimer’s progression. Donanemab and lecanemab target amyloid proteins associated with the disease.
- Treatment options are becoming more flexible. In July 2026, the FDA approved an at-home starting regimen for lecanemab.
- Blood tests are advancing early diagnosis. New diagnostic tools can help physicians identify Alzheimer’s-related changes in certain individuals experiencing cognitive symptoms.
- Researchers are investigating additional therapies. Tau-targeting treatments, research on brain inflammation, and personalized medicine may shape future care.
- Specialized memory care remains essential. Compassionate, individualized support helps families navigate changing needs at every stage.
Donanemab vs. Lecanemab: Comparing New Alzheimer’s Treatments
Donanemab and lecanemab are disease-modifying medications designed to slow Alzheimer’s progression by targeting amyloid in the brain.
Both are intended for eligible individuals with mild cognitive impairment or mild dementia due to Alzheimer’s.
| Feature | Donanemab (Kisunla) | Lecanemab (Leqembi) |
| FDA approval | July 2024 | January 2023 (accelerated); July 2023 (traditional) |
| How it works | Targets amyloid plaques for removal | Targets certain forms of amyloid to reduce buildup |
| Treatment stage | Early symptomatic Alzheimer’s | Early symptomatic Alzheimer’s |
| Administration | Intravenous infusion | Intravenous infusion or approved subcutaneous regimens |
| Primary benefit | Slows cognitive and functional decline | Slows cognitive and functional decline |
Neither medication cures Alzheimer’s or restores memories already lost.
Both also require medical screening and monitoring because of potentially serious side effects.
A neurologist can help determine whether either treatment is appropriate for your loved one.
Explore Personalized Memory Care at Kensington Place Redwood City
New treatments offer possibilities, but every Alzheimer’s journey is different. At Kensington Place Redwood City, our specialized memory care neighborhoods provide individualized support as residents’ needs change.
Discover Our Approach to Alzheimer’s Care
How Do New Alzheimer’s Medications Work?
Alzheimer’s disease causes changes in the brain that gradually affect memory, thinking, communication, and daily functioning.
Two proteins play important roles in the disease:
- Amyloid-beta: Can accumulate into plaques between brain cells.
- Tau: Can form abnormal tangles inside nerve cells, disrupting their function.
Donanemab and lecanemab target amyloid. By helping reduce these deposits, the medications can slow disease progression in certain individuals.
What Research Shows About Donanemab
Donanemab, marketed as Kisunla, is a monoclonal antibody developed by Eli Lilly. The medication binds to certain amyloid plaques, helping the body clear them from the brain.
Clinical trials found that donanemab slowed cognitive and functional decline compared with placebo in individuals with early symptomatic Alzheimer’s disease.
According to the FDA’s clinical trial summary for Kisunla, treatment is administered via intravenous infusion, typically every 4 weeks.
Treatment may be stopped when amyloid levels fall sufficiently, based on a physician’s assessment and appropriate imaging.
What’s New With Lecanemab in 2026?
Lecanemab, marketed as Leqembi, also helps clear amyloid associated with Alzheimer’s.
An important advancement came in July 2026, when the FDA approved a subcutaneous starting regimen using an at-home autoinjector.
This gives eligible individuals another administration option beyond traditional intravenous infusions.
Understanding the Benefits and Risks
Both medications can modestly slow the rate of decline. However, their effectiveness varies, and neither is suitable for everyone.
An important concern is amyloid-related imaging abnormalities (ARIA), which can involve swelling or bleeding in the brain. ARIA may occur without noticeable symptoms, but serious complications are possible.
Before recommending treatment, physicians evaluate factors such as:
- Medical history
- MRI findings
- Certain medications
- Genetic factors, including APOE ε4 status
The goal is to determine whether the potential benefit outweighs the risks for each individual.
New Alzheimer’s Blood Tests May Support Earlier Diagnosis
Early diagnosis has become increasingly important as disease-modifying treatments focus on the earliest symptomatic stages of Alzheimer’s.
Historically, confirming amyloid-related brain changes often required specialized PET imaging or cerebrospinal fluid testing.
Blood-based biomarkers are creating less invasive diagnostic options.
The FDA’s 2025 Blood Test Breakthrough
In May 2025, the FDA cleared the first blood test to aid in diagnosing Alzheimer’s disease.
The test measures biomarkers associated with amyloid plaques in the brain.
- Who it’s for: Adults aged 55 and older experiencing symptoms of cognitive impairment.
- Who it’s not for: It is not intended for routine screening of people without symptoms.
Physicians must interpret results alongside medical history, cognitive assessments, and other appropriate evaluations.
Why Early Detection Matters for Families
Identifying Alzheimer’s earlier can give your loved one more opportunities to participate in important decisions.
It may also help eligible individuals explore treatment while symptoms remain mild.
Early diagnosis gives families time to:
- Discuss treatment options with a neurologist
- Understand changes that may occur as Alzheimer’s progresses
- Establish care preferences and future plans
- Address financial and legal considerations
- Explore caregiving resources and specialized support
If your loved one is experiencing persistent memory changes, consider speaking with their physician.
Learn more about how timely diagnosis can help families explore care options in our guide to early Alzheimer’s detection.
What Promising Alzheimer’s Treatments Are Researchers Studying?
While existing medications target amyloid, scientists are investigating other processes that contribute to Alzheimer’s disease.
The National Institutes of Health’s 2026 Alzheimer’s Research Progress Report highlights advances in biomarkers, experimental therapies, and understanding the biological causes of dementia.
Three research areas are particularly important.
1. Treatments Targeting Tau Proteins
Tau is a protein that helps maintain the structure of healthy nerve cells.
In Alzheimer’s, abnormal tau can form tangles that interfere with communication between brain cells.
Researchers are investigating therapies that could prevent harmful tau changes or reduce their effects. These approaches remain experimental, but they may eventually complement treatments targeting amyloid.
2. Treatments Addressing Brain Inflammation
The brain has its own immune defenses. When inflammatory responses become dysregulated, they may contribute to nerve cell damage.
Scientists are studying whether treatments that influence these responses could help protect brain function.
Researchers are also examining how brain cells manage energy, respond to injury, and clear harmful proteins.
3. Combination and Personalized Therapies
Alzheimer’s involves several biological processes, making it unlikely that one approach will address every aspect of the disease.
Researchers are exploring whether combining treatments could provide additional benefits.
Personalized medicine is another developing area.
Future treatment strategies may increasingly consider:
- Alzheimer’s biomarkers and disease stage
- Genetic risk factors
- Other medical conditions
- Individual responses to treatment
Although these developments are promising, more research is needed to establish their safety and effectiveness in people.
Families should distinguish between an encouraging laboratory discovery, a clinical trial, and an FDA-approved treatment.
What Should Families Consider Before Exploring New Alzheimer’s Treatments?
If someone you love has been diagnosed with Alzheimer’s, it’s natural to want to explore every available option.
However, the newest medication is not always the most appropriate choice.
Treatment decisions depend on your loved one’s diagnosis, medical history, disease stage, and personal preferences.
Five Questions to Ask Your Loved One’s Neurologist
Consider bringing these questions to your next appointment:
- Is my loved one eligible for a disease-modifying treatment? Ask whether their diagnosis and symptoms meet current criteria.
- What tests are needed? Discuss biomarker testing, brain imaging, and other recommended assessments.
- What benefits can we realistically expect? Ask how treatment might affect memory, functioning, or the rate of decline.
- What are the potential risks? Review relevant medical conditions, medications, and required safety monitoring.
- What would treatment involve? Discuss appointments, administration methods, ongoing tests, insurance coverage, and costs.
These conversations can help your family make decisions that balance potential benefits with comfort and quality of life.
What If My Loved One Isn’t Eligible?
Current anti-amyloid medications have not been established as effective treatments for moderate or late-stage Alzheimer’s disease.
However, other forms of support remain available. Depending on individual needs, a physician may recommend medications that help manage certain cognitive or behavioral symptoms.
Supportive care can also address challenges involving:
- Daily activities
- Communication
- Sleep
- Nutrition
- Emotional well-being
Families may consider specialized memory care when a loved one needs more assistance or supervision than can comfortably be provided at home.
The focus becomes finding the right combination of medical guidance, daily support, and meaningful engagement.
Have Questions About Your Loved One’s Changing Care Needs?
We understand that navigating Alzheimer’s can bring difficult decisions, especially when your loved one’s needs are changing.
At Kensington Place Redwood City, our team is here to listen, answer your questions about memory care, and help you explore what comes next.
Connect With Our Memory Care Team
How Kensington Place Redwood City Supports Residents Living With Alzheimer’s
Medical advancements may change how Alzheimer’s is treated, but daily support remains an important part of living well with memory loss.
At Kensington Place Redwood City, we recognize that each resident has a unique history, personality, and set of needs.
Through individualized care and specialized memory care neighborhoods, we help residents receive appropriate support as their abilities change.
Connections: Early to Middle-Stage Memory Care
Our Connections neighborhood supports residents in the early to middle stages of Alzheimer’s and other forms of dementia.
We focus on helping residents remain involved in meaningful activities while receiving assistance with changing cognitive and daily needs.
Our approach emphasizes:
- Encouraging independence whenever possible
- Maintaining familiar, reassuring routines
- Supporting social connection and purposeful engagement
- Providing assistance as memory and functional abilities change
By focusing on each resident’s strengths, we strive to help them continue participating in the activities and relationships that matter.
Haven: Advanced Memory Care With Comfort and Dignity
Our Haven neighborhood serves residents experiencing more advanced stages of dementia.
As Alzheimer’s progresses, individuals may require greater assistance with personal care, mobility, communication, and everyday activities.
Haven provides a supportive environment where our team members emphasize comfort, safety, and compassionate assistance.
Personalized Care That Adapts to Your Loved One
Our specialized memory care approach addresses the changing needs of residents and the concerns of their families.
At Kensington Place Redwood City, we offer:
- Individualized care plans reflecting residents’ abilities, preferences, and personal histories.
- On-site licensed nursing 24 hours a day, seven days a week to support ongoing care needs.
- Specialized memory care team members experienced in supporting individuals living with dementia.
- Personalized life enrichment that encourages participation based on individual interests and abilities.
- Family involvement and support to help loved ones remain connected throughout the care journey.
Our goal is to provide continuity, reassurance, and care that respects each resident’s individuality.
We invite you to learn more about what makes our memory care approach different.
FAQs: New Alzheimer’s Treatments
Donanemab and lecanemab are FDA-approved disease-modifying medications for Alzheimer’s, with treatment initiated during the early symptomatic stages. Donanemab received approval in July 2024. Lecanemab received traditional approval in July 2023, following accelerated approval earlier that year. In July 2026, the FDA also approved an at-home subcutaneous starting regimen for lecanemab.
FDA-cleared blood tests can help physicians identify Alzheimer’s-related biomarkers in certain symptomatic adults. However, results must be interpreted alongside other clinical information. A blood test alone does not replace a comprehensive medical evaluation.
Current anti-amyloid medications were studied in individuals with mild cognitive impairment or mild dementia due to Alzheimer’s. Their effectiveness in later stages has not been established. For individuals with advanced dementia, personalized medical care, symptom management, and specialized memory care remain important.
Hope for Tomorrow, Compassionate Memory Care Today
Alzheimer’s research continues to bring meaningful progress.
For families, these discoveries offer reasons to remain hopeful as they make thoughtful decisions about care today.
At Kensington Place Redwood City, we believe every person living with memory loss deserves compassion, dignity, and opportunities for meaningful connection.
Discover the Kensington Difference. Schedule a Private Tour.
Choosing memory care is an important family decision. We invite you to visit our community, meet our team members, and learn how we support residents in our Connections and Haven neighborhoods.